ADVERTISEMENT
Cipla Q4 Results Review: Dolat Capital Maintains 'Add' Rating, Hikes Target Price — Here's Why
Earlier than expected launches of gAbraxane or gAdvair will be an upside its estimates, says Dolat Capital.
14 May 2025, 10:25 AM IST 
. (Photo source: NDTV Profit)
Dolat Capital believes that ex Revlimid margin trajectory will sustain from focus on differentiated launches in the US and traction in the South Africa business and One India business. Earlier than expected launches of gAbraxane or gAdvair will be an upside to the brokerage's estimates.
I’m already a Subscriber
To continue reading this storySubscribe to Unlock & Enjoy your
Subscriber-Only benefits
Subscriber-Only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Subscriber-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Subscriber-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
